### Analysis:

Johnson & Johnson's Q3 2017 earnings were robust, with strong performance across all segments. The company reported record sales and earnings, driven by pharmaceuticals and consumer products. The medical devices segment was relatively stable, but faced some headwinds from weather-related events and market competition. The company's guidance for 2017 was maintained, with a focus on continued investment in growth opportunities and new product launches. The stock is likely to face short-term pressure due to tempered guidance and uncertainties around key defense contracts. The company's strategic growth initiatives and strong pipeline of new products suggest long-term potential.

### Conclusion:

The short-term (1â€“2 weeks) impact on the stock price is likely to be:

-2